Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib extension study in adults with chronic spontaneous urticaria after prior phase III studies
CTR20230631Phase 3Active
- Sponsor
- 不适用/ 诺华（中国）生物医学研究有限公司
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of remibrutinib in chronic idiopathic urticaria (CIU), sponsored by 不适用/ 诺华（中国）生物医学研究有限公司. Started May 2023; status: active.
02
Drugs
remibrutinib
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on CTR20230631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230631.